An expert discusses the multifaceted nature of CAR T-cell therapy for relapsed/refractory (R/R) large B-cell lymphoma (LBCL), emphasizing the need for early multidisciplinary coordination to address clinical, logistical, financial, and psychosocial challenges, ensuring patients are supported throughout the complex treatment journey.
An expert discusses the evolving management of relapsed/refractory (R/R) large B-cell lymphoma (LBCL), illustrating how CAR T-cell therapy has transformed third-line treatment from palliative to potentially curative, and emphasizing the importance of timely referral, reassessing eligibility, and individualizing care to optimize patient outcomes.
An expert discusses how optimal sequencing of therapies remains unclear in lower-risk MDS, with emerging combination strategies and ongoing trials that may help define the best treatment approaches.
An expert discusses how real-world evidence and patient-reported outcomes support luspatercept’s clinical benefits, while highlighting the high failure rates of ESA therapy in community practice.
Panelists discuss how implementing combination immunotherapy in clinical practice faces institutional barriers, including formulary approval for retifanlimab and payer authorization challenges. They maintain that published dosing schedules should be followed rather than modifying treatment intervals to address patient access barriers.
Panelists discuss how biomarker development in anal cancer remains limited with PD-L1 status not influencing treatment decisions, although rare targets like HER2, PIK3CA aberrations, and RAS wild-type status for EGFR inhibitors may warrant next-generation sequencing testing for research purposes, while emphasizing honest discussions about palliative treatment goals and quality-of-life balance.
An expert discusses that while CAR T-cell therapy has transformed the treatment landscape for primary refractory diffuse large B-cell lymphoma by outperforming traditional transplant approaches in the second-line setting, timely referral to specialized centers is critical, as misjudged eligibility and nonclinical barriers like geography, caregiver support, and insurance can delay or prevent access to this potentially curative therapy—challenges best addressed through proactive, multidisciplinary coordination.
An expert discusses that this case of a 60-year-old man with primary refractory diffuse large B-cell lymphoma highlights the urgent need for a shift in therapeutic strategy following early relapse after R-CHOP, with CAR T-cell therapy emerging as a preferred option given the poor prognosis of chemo-refractory disease, the patient’s eligibility for intensive treatment, and the critical role of timely referral, coordinated care, and transparent communication to optimize outcomes in high-risk lymphoma.
An expert discusses the importance of timely biomarker testing and emerging challenges in treatment sequencing for metastatic triple-negative breast cancer (mTNBC), as first-line use of antibody-drug conjugates (ADCs) raises concerns about cross-resistance and the need for strategic postprogression planning.
An expert discusses the evolving role of biomarker testing in first-line metastatic triple-negative breast cancer (mTNBC), highlighting how PD-L1, BRCA status, and emerging markers such as Trop-2 expression are shaping personalized treatment approaches and guiding the integration of antibody-drug conjugates (ADCs) and immunotherapy.
An expert discusses how long-term follow-up data from the COMMANDS trial demonstrated sustained superiority of luspatercept over ESAs, with an intriguing trend toward improved overall survival that warrants further investigation.
An expert discusses how the EPO-PRETAR trial results showed no significant difference in transfusion dependence between early and late ESA initiation, emphasizing that treatment timing remains an individualized decision.
An expert discusses how radiopharmaceuticals such as radium-223 offer a valuable different mechanism of action in treating advanced prostate cancer, requiring careful patient selection, safety monitoring including complete blood count (CBC) tracking, and practical management of adverse effects such as fatigue and nausea while following radiation safety protocols.
Panelists discuss how treatment selection between combination immunotherapy (IO) and chemotherapy alone should favor the FDA-approved carboplatin-paclitaxel-retifanlimab regimen for most patients with metastatic anal cancer, while avoiding checkpoint inhibitors in solid organ transplant recipients and maintaining that different checkpoint inhibitors are not necessarily interchangeable without specific trial data.
Panelists discuss how the PODIUM-303 study demonstrated improved progression-free survival (9.3 vs 7.4 months) and response rates (56% vs 44%) when adding retifanlimab to carboplatin-paclitaxel in first-line metastatic anal cancer, leading to FDA approval despite nonsignificant overall survival results due to 45% crossover in the interim analysis.
An expert discusses how emerging trial data, particularly from ASCENT-04, are reshaping first-line treatment strategies for PD-L1–positive metastatic triple-negative breast cancer (mTNBC) by demonstrating the potential superiority of antibody-drug conjugates (ADCs) combined with immunotherapy over standard chemotherapy regimens.
An expert discusses how recent clinical advancements and biomarker-driven strategies are reshaping first-line treatment decisions in metastatic triple-negative breast cancer (mTNBC), emphasizing the critical need for early, optimized therapy to improve outcomes in this aggressive disease.
A panelist notes that while new treatments like luspatercept and imetelstat offer hope beyond traditional erythropoiesis-stimulating agents—which fail in many patients and provide limited response duration—variability in patient response, influenced by factors such as mutation burden, underscores the need for personalized therapies and continued development of agents that can modify disease progression and improve survival in low-risk myelodysplastic syndrome.
A panelist highlights that after initial hemoglobin decline despite dose escalation, further increasing luspatercept dosing led to transfusion independence and hemoglobin improvement, underscoring the critical role of regular monitoring and timely dose adjustments to optimize anemia management in low-risk myelodysplastic syndrome.
An expert discusses how the PEACE III combination of radium-223 and enzalutamide represents an effective treatment option for the limited population of patients who reach first-line metastatic castration-resistant prostate cancer (mCRPC) without prior androgen receptor pathway inhibitor exposure, while other combinations such as radium-223 plus olaparib showed mixed results with concerning toxicity profiles.
A panelist emphasizes that recent real-world retrospective data from 103 first-line luspatercept-treated patients closely align with, and even slightly exceed, COMMANDS trial results—demonstrating significant hemoglobin improvements and transfusion independence—thereby reinforcing luspatercept’s effectiveness and practical value in routine clinical care for erythropoiesis-stimulating agent–naïve, low-risk patients with myelodysplastic syndrome.
An expert discusses how CT scans and bone scans remain the standard imaging approach for most patients with metastatic castration-resistant prostate cancer (mCRPC), whereas prostate-specific membrane antigen (PSMA) PET scans are primarily reserved for selecting patients for specific treatments such as lutetium Lu 177 vipivotide tetraxetan (Pluvicto), though they may offer better sensitivity for detecting soft tissue disease in radium-223 candidates.
A panelist highlights that updated COMMANDS trial data demonstrate luspatercept’s robust efficacy in erythropoiesis-stimulating agent–naive patients with low-risk myelodysplastic syndrome—achieving high rates of durable transfusion independence and hemoglobin improvement across subgroups—with emerging evidence suggesting potential long-term survival benefits and a favorable safety profile.
Panelists discuss how current NCCN guidelines for metastatic anal cancer recommend carboplatin-paclitaxel as preferred first-line therapy, with the recent addition of carboplatin-paclitaxel plus retifanlimab as category 2B evidence following FDA approval, while noting that induction chemotherapy for bulky disease remains case-specific without randomized data support.
Panelists discuss how a woman aged 55 years with T3N1M0 locally advanced squamous cell carcinoma represents a typical case for definitive chemoradiation therapy over surgical resection, emphasizing the importance of supportive care measures, including pain management, hydration monitoring, and patient education, to optimize treatment completion rates and minimize toxicity.
An expert discusses how the treatment landscape for lower-risk MDS has evolved with multiple new options including luspatercept, imetelstat, and lenalidomide based on specific patient characteristics like ring sideroblast status and EPO levels.
An expert discusses how a 67-year-old woman with symptomatic anemia was diagnosed with lower-risk MDS and treated with luspatercept as first-line therapy.
A panelist emphasizes that treatment decisions for anemia in low-risk myelodysplastic syndrome should be guided by symptoms and functional status rather than strict hemoglobin thresholds, with erythropoiesis-stimulating agents or luspatercept often initiated before transfusion dependence to improve quality of life and potentially delay disease progression.
Panelists discuss how the future treatment landscape for myeloproliferative neoplasms is evolving with many promising therapies in development, including calreticulin antibodies, selective JAK2 inhibitors, and novel agents targeting various pathways.
A panelist explains how the distinct mechanisms of erythropoiesis-stimulating agents (ESAs), luspatercept, and imetelstat offer tailored treatment options for anemia in lower-risk ESAs, enabling clinicians to address different stages of erythropoiesis and disease biology to optimize patient outcomes.